Related Experiment Video
Updated: Apr 12, 2026
09:29
Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells
Published on: March 5, 2019
6.1K
Endothelin antagonism and hypertension: an evolving target.
Luke J Laffin1, George L Bakris1
1American Society of Hypertension Comprehensive Hypertension Center, Department of Medicine, University of Chicago Medicine, Chicago, IL.
Seminars in Nephrology
|May 13, 2015
Summary
Endothelin receptor antagonists effectively treat primary and resistant hypertension but have limited use due to side effects and alternatives. Newer, selective antagonists show promise for specific hypertension subtypes.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Endothelin antagonism is studied for hypertension management.
- Endothelin-receptor antagonists are effective for primary and resistant hypertension.
- Limited use is due to side effects and alternative treatments.
Purpose of the Study:
- To review the impact of endothelin antagonism in hypertension.
- To explore evolving research on endothelin and hypertension.
- To discuss new applications of selective endothelin-receptor antagonists.
Main Methods:
- Review of preclinical and clinical studies.
- Analysis of data on endothelin's role in hypertension.
- Evaluation of selective endothelin-receptor antagonists.
Main Results:
- Endothelin-receptor antagonists show efficacy in hypertension.
- Side effects and available alternatives limit their widespread use.
- Selective antagonists may benefit specific hypertension subtypes.
Conclusions:
- Endothelin antagonism is a viable, though underutilized, hypertension therapy.
- Evolving research suggests targeted benefits for selective antagonists.
- Further investigation into specific patient populations is warranted.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
568
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
568
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:29Hypertension II: Pathophysiology
1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K